BioMarin submits EU marketing application for vosoritide
If approved, vosoritide would be the first medicine for the treatment of achondroplasia – the most common form of short stature – in Europe
Read More
Tag: short stature
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
